Enumeral Biomedical Holdings Inc
Enumeral Biomedical — Investor Presentation (March 2016)
40 slides from Enumeral Biomedical's investor presentation, Mar 11, 2016
Slide 1: Corporate Overview March 2016
Corporate Overview March 2016
Slide 2: Company Highlights
Company Highlights • Enumeral is an antibody immuno - oncology company based on technology developed at Harvard and MIT • Enumeral’s differentiated PD - 1 antagonist C8 has potential to become best - in - class cancer immunotherapy – Novel mechanism of binding leads to in vitro enhanced activity – S
Slide 3: Agenda
Agenda 1. The Opportunity for Best - in - Class PD - 1 Antagonist 2. ENUM C8 – A Differentiated Anti - PD - 1 Antibody That Drives Adaptive and Innate Immune Cell Activation 3. TIM - 3 – Next Program; Additional Pipeline Programs 4. Clinical Opportunity and Development Plan 5. Platform and IP 6. Col
Slide 4: Large Market Opportunity Exists For A More Effective Directed Therapy
Large Market Opportunity Exists For A More Effective PD - 1 Directed Therapy 4 Non responders Responders Value to payors if new products treat prior therapy failures and relapse Estimated sales for checkpoint blockers in 2020 $27 billion per year* (Estimate only for PD - 1/PD - L1 class ) *Cowen and
Slide 5: Limitations of First Generation Inhibitors
Limitations of 1 st generation PD - 1 inhibitors PD - 1 blockade through disrupting the PD - L1 interaction is an incomplete solution • In the approved indications, response rates are around 20% • Ability to predict responders based on PD - 1 or PDL - 1 expression is disappointing • Ability to predi
Slide 6: ENUM Solution: A Differentiated Antibody
ENUM Solution: A Differentiated PD - 1 Antibody ENUM Platform - Generated antibody C8 • May act on PD - 1 through non competitive mechanism • Does not disrupt PD - L1 interaction with PD - 1 • May Activate both Active and Innate immune systems • Translational approach leverages human biopsy profilin
Slide 7: Agenda
Agenda 1. The Opportunity for Best - in - Class PD - 1 Antagonist 2. ENUM C8 – A Differentiated Anti - PD - 1 Antibody That Drives Adaptive and Innate Immune Cell Activation 3. TIM - 3 – Next Program; Additional Pipeline Programs 4. Clinical Opportunity and Development Plan 5. Platform and IP 6. Col
Slide 8: ENUM C8 Reverses PD-L1 Suppression
ENUM C8 Reverses PD - L1 Suppression 8 C8 Antibody in Cell - Based Assays: T Cell Activation IFNg secretion (relative to control) N = 5 repetitions for each candidate/condition • PBMC - based assay to determine mAb’s ability to disrupt functional suppression by PD - L1 • Pembrolizumab used as positi
Slide 9: ENUM C8 Does Not Disrupt The Interaction between PD-L1 and PD-1
ENUM C8 Does Not Disrupt The Interaction between PD - L1 and PD - 1 9 No displacement of PD - L1 by ENUM C8 • PD1 - expressing HEK293 incubated with controls (isotype, negative control; EH12.2H7, positive control) and test antibodies D4 and C8 • Cells retaining labeled PD - L1 reagent visualize with
Slide 10: ENUM C8 Acts via Allosteric Mechanism
ENUM C8 Acts via Allosteric Mechanism 10 PD - L1 engagement results in T cell inhibition Current anti - PD1 agents disrupt PD - L1 binding to PD - 1 Hypothesis: ENUM anti - PD1: novel epitope and PD - L1 independent binding; IL - 2R autocrine activation enhanced T cell activation ENUM antibody: PD -
Slide 11: ENUM C8 may have Multiple Actions in the Cancer Immunity Cycle
ENUM C8 may have Multiple Actions in the Cancer Immunity Cycle 11 Oncology Meets Immunology: The Cancer - Immunity Cycle ; Daniel S. Chen, Ira Mellman Immunity; Volume 39, Issue 1, Pages 1 - 10 (July 2013) Cancer Immunity Cycle pembro nivo C8 Ag presentation x Priming & activation x Killing x x x 2
Slide 12: C8 Inhibits Tumor Growth in Mouse Model with Re-constituted Human T Cell Lineages
C8 Inhibits Tumor Growth in Mouse Model with Re - constituted Human T Cell Lineages 12 Tumor size (mm 3 ) 0 3 6 10 13 17 20 24 28 0 250 500 750 1000 1250 Group 1: Vehicle Group 2: 388D4 Group 3: 244C8 Group 4: Pembrolizumab Day 95% confidence interval plotted Studies performed by The Jackson Laborat
Slide 13: D - H C + L C D - H C + L C
D 4 - H C 3 + L C 1 D 4 - H C 1 + L C 3 D 4 - H C 3 + L C 3 C 8 - H C 1 + L C 1 C 8 - H C 1 + L C 3 C 8 - H C 2 + L C 1 N i v o - I g G 4 h I g G 4 - H C A 2 4 7 0 5000 10000 MLR Donor 337+23 (IFNy) I F N y ( p g / m l ) 10 ug/ml 1 ug/ml 0.1 ug/ml 0.01 ug/ml Antibody concentration Antibody concentra
Slide 14: ENUM C8 Elicits Cytokine Signature Consistent with Activation of Innate Immunity
ENUM C8 Elicits Cytokine Signature Consistent with Activation of Innate Immunity 14 Ex vivo cytokine production in NSCLC tumor biopsy consistent with focal activation of both innate & adaptive anti - tumor immunity B i o e g e n d I g G 4 ( 1 0 u g / m L ) 3 8 8 D 4 - 2 ( 1 0 u g / m L ) 2 4 4 C 8 -
Slide 15: C8 Mechanism is CD40L-Dependent
C8 Mechanism is CD40L - Dependent: Consistent with Linkage of Adaptive and Innate Immunity 15 Kambayashi & Laufer NRI 2014 CMV recall assay with C8 PD1 blockade ± CD40L blockade These data suggest C8 - based PD1 blockade potentiates both T cell activation ( IFNg ) & APC (IL - 12) activation 2
Slide 16: Summary: Rational Basis for C8-dependent Enhanced Immune Activation
Summary: Rational Basis for C8 PD - 1 - dependent Enhanced Immune Activation 16 • First - generation drugs optimized for effects on T cells* but T cells do not act alone in the TME • C8 may differentially drive cross - talk between adaptive and innate immune cells in the TME via cytokine secretion •
Slide 17: Agenda
Agenda 1. The Opportunity for Best - in - Class PD - 1 Antagonist 2. ENUM C8 – A Differentiated Anti - PD - 1 Antibody That Drives Adaptive and Innate Immune Cell Activation 3. TIM - 3 – Next Program; Additional Pipeline Programs 4. Clinical Opportunity and Development Plan 5. Platform and IP 6. Col
Slide 18: TIM-3 Program Rationale
TIM - 3 Program Rationale • TIM - 3 expression often correlates with PD - 1 expression in vivo • TIM - 3 may drive T cell exhaustion and adaptive resistance following PD - 1 blockade • Anti - TIM - 3 alone or in combinations with anti - PD - 1 or other immuno - oncology agents may result in enhanced
Slide 19: Overview: ENUM TIM-3 Program
Overview: ENUM TIM - 3 Program • Exceptional sequence diversity of anti - TIM - 3 antibodies – Many ENUM TIM - 3 candidates result in greater T cell function than a TIM - 3 reference antibody – Implies ENUM TIM - 3 antibodies are potent – Multiple potential leads supporting drug candidate selection
Slide 20: TIM-3 Program Diversity Supports Development of Differentiated Candidates
TIM - 3 Program Diversity Supports Development of Differentiated Candidates 20 *Based on ENUM evaluation of published literature Dendrogram showing bioinformatics analysis of Vh amino acid sequence among selected ENUM anti - TIM - 3 antibodies and known patented antibodies. • TIM - 3 target complexi
Slide 21: ENUM TIM3 Antibodies are Potent: CD4 T Cell Stimulation
ENUM TIM3 Antibodies are Potent: CD4 T Cell Stimulation 21 TIM3 Ab 1ug/ml IFNr pg/ml 100812_E1VH3100814_F2VH1100814_G1VH7100878_F1VH7100666_D1VH72e2 mIgG1 0 100 200 300 400 500 100812_E1VH3 100814_F2VH1 100814_G1VH7 100878_F1VH7 100666_D1VH7 2e2 mIgG1 Suboptimal CD3/CD28 - based stimulation of human
Slide 22: ENUM Anti-TIM3 Antibody Activates Blockade-Refractory NSCLC TILs Ex Vivo
ENUM Anti - TIM3 Antibody Activates PD - 1Blockade - Refractory NSCLC TILs Ex Vivo 22 m I g G 1 k ( 1 u g / m L ) T I M - 3 # 5 ( 1 u g / m L ) 2 4 4 c 8 ( 1 0 u g / m L ) + T i m 3 # 5 ( 1 u g / m L ) 0 5000 10000 15000 I F N - ( p g / m L ) Isotype control Tumor WD - 22 NSCLC tumor WD - 22 was ref
Slide 23: Enumeral TIM3 Program Summary
Enumeral TIM3 Program Summary • Identification of multiple potent potential lead candidates • Evaluation of NSCLC tumors demonstrates: – Heterogeneity of response to immune checkpoint blockade • TIM - 3 blockade can activate PD - 1 blockade - refractory TILs ex vivo • Human biopsy - based rationale
Slide 24: Other Enumeral Pipeline Programs
Other Enumeral Pipeline Programs BMS Immutep 24 GSK • ENUM LAG - 3 Antibodies To - Date: Broad Diversity – 102 Sequences – 40 Families – Encompass known published antibody space* • Other Screening Programs: – TIGIT – VISTA – OX40 – Others not disclosed Dendrogram showing bioinformatics analysis of V
Slide 25: Agenda
Agenda 1. The Opportunity for Best - in - Class PD - 1 Antagonist 2. ENUM C8 – A Differentiated Anti - PD - 1 Antibody That Drives Adaptive and Innate Immune Cell Activation 3. TIM - 3 – Next Program; Additional Pipeline Programs 4. Clinical Opportunity and Development Plan 5. Platform and IP 6. Col
Slide 26: Clinical Opportunity for Next Generation Checkpoint Blockers
Clinical Opportunity for Next Generation Checkpoint Blockers 26 Non responders Responders Opportunity: new products to treat prior therapy failures and relapse Resistant or refractory patients Goal: improve aggregate response rates Eligible patients
Slide 27: Enumeral Pipeline
Enumeral Pipeline 27 ENUM 244C8 • Novel allosteric mechanism of binding leads to enhanced activity in vitro • Binding: differentiated epitope • Novel composition of matter • Potential mechanism of action through coordinated activation of adaptive and innate immunity TIM - 3 • Broad diversity of anti
Slide 28: ENUM C8, D4 and other Pipeline Antibodies have Potential to Address Unmet Clinical Need
ENUM C8, D4 and other Pipeline Antibodies have Potential to Address Unmet Clinical Need 28 Checkpoint blockade improves efficacy of other modalities Potential to treat relapse and refractory PD - 1 patients: expand into open label registration trial Checkpoint combination inhibition may treat resist
Slide 29: Agenda
Agenda 1. The Opportunity for Best - in - Class PD - 1 Antagonist 2. ENUM C8 – A Differentiated Anti - PD - 1 Antibody That Drives Adaptive and Innate Immune Cell Activation 3. TIM - 3 – Next Program; Additional Pipeline Programs 4. Clinical Opportunity and Development Plan 5. Platform and IP 6. Col
Slide 30: Proprietary Platform Drives Discovery and Development Advantage
Proprietary Platform Drives Discovery and Development Advantage 30 84,672 50µm microwells • Proprietary broadly enabling “Immune system on a chip” platform • Immuno - oncology still a “black box” – Requires mechanistically differentiated assets for entry – Requires translational biology insights to
Slide 31: Primary Human Tumor Biopsy Approach Drives Translational Antibody Selection
Primary Human Tumor Biopsy Approach Drives Translational Antibody Selection 31 function phenotype genomics Patient - centric integrated single cell functional immune profiling of antibody modulation of cytokine secretion and receptor expression Patient biopsy Enumeral has developed a translational c
Slide 32: Enumeral Research Activities
Enumeral Research Activities 32 Antibody Discovery Target Discovery and Validation In Vitro Pharmacology Tumor Profiling, TCR, Genomics Cell Based Assays Lead discovery Translational & Clinical Sciences Clinical strategy & ITT cohort identification Target ID & Nomination Development Candidate
Slide 33: Diversity leads to Differentiated Antibodies
Diversity leads to Differentiated Antibodies • Enumeral antibody discovery results in exceptional diversity* • Drives empirical function - based approach: diversity is key to identifying potential ‘best - in - class’ candidates using primary biopsy validation • Potential for strong IP position OPDIV
Slide 34: Strong Intellectual Property Position
Strong Intellectual Property Position • Exclusive worldwide license with MIT/Harvard for platform technology – 6 issued patents in US and 32 issued in international jurisdictions – 26 pending patent applications (US & International) • Patents covering compositions of matter and methods – Application
Slide 35: Agenda
Agenda 1. The Opportunity for Best - in - Class PD - 1 Antagonist 2. ENUM C8 – A Differentiated Anti - PD - 1 Antibody That Drives Adaptive and Innate Immune Cell Activation 3. TIM - 3 – Next Program; Additional Pipeline Programs 4. Clinical Opportunity and Development Plan 5. Platform and IP 6. Col
Slide 36: Collaborators Provide External Recognition of Differentiated Approach
Collaborators Provide External Recognition of Differentiated Approach • MERCK : collaboration with a leading immuno - oncology pharmaceutical company – Focused on using Enumeral's platform to interrogate the tumor microenvironment in colorectal cancer tissues to identify functional cellular response
Slide 37: Strategic Collaboration with MD Anderson Cancer Center
Strategic Collaboration with MD Anderson Cancer Center • Goal to Discover and Develop Novel Antibodies Against Specified Immunotherapy Targets – Utilizes Enumeral’s antibody discovery and patient - centric immune profiling platform – Leverages MD Anderson’s preclinical and development expertise and
Slide 38: Experienced Leadership Team
Experienced Leadership Team 38 John J. Rydzewski Executive Chairman, Co - Founder, Director Arthur H. Tinkelenberg, Ph.D. President & CEO, Co - Founder, Director Cokey Nguyen, Ph.D. Vice President, Research & Development Isabel Chiu, Ph.D. Vice President, Translational & Clinical Sciences Kevin G. S
Slide 39: Non-Management Directors
Non - Management Directors 39 Barry Buckland, Ph.D. Co - Founder; Chairman, Scientific Advisory Board Robert J. Easton Allan Rothstein Paul J. Sekhri Robert L. Van Nostrand
Slide 40: THE POWER of HUMAN
THE POWER of HUMAN™
Enumeral Biomedical Holdings — Investor Presentation (March 2016) on 6ix